Bal Pharma Ltd. (BSE: 524824) is a Bengaluru, Karnataka-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹140 Cr, it ranks #2,956 by market cap among the 6,197 Indian listed companies on FinBizNet, and #62 of 86 in Medicinal Chemicals and Botanical Products. At ₹91.00 (as of 16 Nov 2026), the share price is 27.0% below its 52-week high of ₹124.60 and 51.7% above its 52-week low of ₹60.00. The share price is up 13.2% over one year and up 3.1% over three months.
| Current Price | ₹91.00 |
|---|---|
| Market Cap | ₹140 Cr |
| BSE Code | 524824 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 22.4 |
| Return on Equity | 7.92% |
| Return on Assets | 3.35% |
| 52-Week Range | ₹60.00 – ₹124.60 |
| 1-Year Price Change | +13.2% |
| 3-Month Price Change | +3.1% |
| Beta (1Y) | 0.73 |
| Dividend Yield | 1.36% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.balpharma.com |
| Revenue | ₹90 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 1.6% |
| EPS (Basic) | ₹0.89 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bal Pharma Ltd. reported revenue of ₹90 Cr in Q2 FY27, up 21.5% from ₹74 Cr in Q2 FY26 and up 1.5% from ₹89 Cr in Q1 FY27. It posted a net profit of ₹1 Cr for the quarter, against a net profit of ₹1 Cr in Q2 FY26 (up 98.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹66 Cr (Q1 FY26) to ₹90 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹90 Cr | ₹1 Cr | 1.6% |
| Q1 FY27 | ₹89 Cr | ₹1 Cr | 1.3% |
| Q4 FY26 | ₹84 Cr | ₹4 Cr | 4.3% |
| Q3 FY26 | ₹88 Cr | ₹2 Cr | 2.0% |
| Q2 FY26 | ₹74 Cr | ₹1 Cr | 1.0% |
| Q1 FY26 | ₹66 Cr | ₹0 Cr | 0.3% |
| Q4 FY25 | ₹82 Cr | ₹5 Cr | 6.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 50.86% of Bal Pharma Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs f
1. Manufacturing of Pharmaceuticals-This segment engages in the manufacture and marketing of pharmaceutical formulations and active pharmaceutical ingredients in India. It offers prescription drugs, generics, OTC products, intravenous infusions, and bulk actives.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Bal Pharma Ltd. | ₹140 Cr | 22.4 | 7.92% | ₹90 Cr | +13.2% |
Listed by market capitalisation. Ratios are shown for context only.
Bal Pharma Ltd. is trading at ₹91.00, with a market capitalisation of ₹140 Cr.
Bal Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Bal Pharma Ltd. has a P/E of 22.4 and a return on equity of 7.92%.
Bal Pharma Ltd. is listed on the BSE under the scrip code 524824.
Bal Pharma Ltd.'s share price is up 13.2% over one year and up 3.1% over three months. Its 52-week range is ₹60.00 to ₹124.60.
In Q2 FY27, Bal Pharma Ltd. reported revenue of ₹90 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.89 (consolidated, parsed from the company's exchange filing).
Bal Pharma Ltd. reported revenue of ₹90 Cr in Q2 FY27, up 21.5% from ₹74 Cr in Q2 FY26 and up 1.5% from ₹89 Cr in Q1 FY27.
Promoters held 50.86% of Bal Pharma Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.